✦ LIBER ✦

1043 PENTOXIFYLLINE (PTX) REDUCES THE RISK OF COMPLICATIONS IN PATIENTS WITH ADVANCED CIRRHOSIS. ANALYSIS OF THE RESULTS OF A PIVOTAL PHASE 3 TRIAL

✍ Scribed by Lebrec, D.; Thabut, D.; Oberti, F.; Perarnau, J.-M.; Condat, B.; Barraud, H.; Saliba, F.; Carbonell, N.; Renard, P.; Ramond, M.-J.; Moreau, R.; Poynard, T.

Book ID: 122028288
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(09)61045-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

66 Rifaximin Reduces the Risk of Hospita

66 Rifaximin Reduces the Risk of Hospitalizations in Patients with Previous Episodes of Hepatic Encephalopathy: Results from a Phase 3 Placebo-Controlled Trial

✍ Guy Neff; Carroll B. Leevy; Todd Frederick; Kunal Merchant; Shirley Huang; Audre 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 158 KB

PSY18 A DECISION ANALYSIS MODEL EXPLORIN

PSY18 A DECISION ANALYSIS MODEL EXPLORING THE RESULTS OF A PHASE II TRIAL OF ELTROMBOPAG FOR PATIENTS WITH CHRONIC HEPATITIS C, CIRRHOSIS AND THROMBOCYTOPENIA

✍ J. Schelfhout; T. Kauf 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Intravesical Bacillus Calmette-Guerin Re

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

✍ SYLVESTER, RICHARD J.; van der MEIJDEN, ADRIAN P.M.; LAMM, DONALD L. 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 267 KB

Encephalopathy is the dose-limiting toxi

Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies

✍ Richard A. Larson, Robert B. Geller, Linda Janisch… 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 673 KB

401 The incidence of antimuscarinic-asso

401 The incidence of antimuscarinic-associated side effects in overactive bladder (OAB) patients treated with mirabegron: Results of a pooled analysis of 3 randomised phase 3 trials

✍ Nitti, V.; Chapple, C.R.; Amarenco, G.; Radziszewski, P.; Angulo, J.; Blauwet, M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 294 KB

Final results of a double-blind, placebo

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

✍ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 2 views

## Interferon-␥1b (IFN-␥1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati